Bicycle TherapeuticsFRA:50BA 57 Piotroski F-Score is 2 as of Jun. 26, 2026, which is 33% below its 10-year median of 3.00. GuruFocus rates FRA:50BA with a GF Score™ of 57/100 and a GF Value™ of €12.98 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 1,342 Biotechnology companies, Bicycle Therapeutics ranks worse than 73.1% on this metric.
Warning Sign:
Piotroski F-Score of 2 is low, which usually implies poor business operation.
The zones of discrimination were as such:
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Bicycle Therapeutics has an F-score of 2. It is a bad or low score, which usually implies poor business operation.
The historical rank and industry rank for Bicycle Therapeutics's Piotroski F-Score or its related term are showing as below:
FRA:50BA'
s Piotroski F-Score Range Over the Past 10 Years
Min: 1 Med: 3 Max: 4
Current: 2
During the past 9 years, the highest Piotroski F-Score of Bicycle Therapeutics was 4. The lowest was 1. And the median was 3.
The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.
He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.
He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.
What he found was something that exceeded his most optimistic expectations.
Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.
Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).
Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.
Bicycle Therapeutics Piotroski F-Score Related Terms
Bicycle Therapeutics Piotroski F-Score Historical Data
* Premium members only.
The historical data trend for Bicycle Therapeutics's Piotroski F-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:50BA vs ABEO, DMAC, FATE: Piotroski F-Score Comparison
For the Biotechnology subindustry, Bicycle Therapeutics's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bicycle Therapeutics Piotroski F-Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bicycle Therapeutics's Piotroski F-Score distribution charts can be found below:
* The bar in red indicates where Bicycle Therapeutics's Piotroski F-Score falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.
Profitability
Question 1. Return on Assets (ROA)
Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Bicycle Therapeutics's current Net Income (TTM) was -188.63.
==> Negative ==> Score 0.
Question 2. Cash Flow Return on Assets (CFROA)
Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Bicycle Therapeutics's current Cash Flow from Operations (TTM) was -197.29.
==> Negative ==> Score 0.
Question 3. Change in Return on Assets
Compare this year's return on assets (1) to last year's return on assets.
Bicycle Therapeutics's return on assets of this year was -0.23071128. Bicycle Therapeutics's return on assets of last year was -0.37442687.
==> This year is higher. ==> Score 1.
Question 4. Quality of Earnings (Accrual)
Compare Cash flow return on assets (2) to return on assets (1)
Bicycle Therapeutics's gearing of this year was 0.01782073. Bicycle Therapeutics's gearing of last year was 0.00293186.
==> Last year is lower than this year ==> Score 0.
Question 6. Change in Working Capital (Liquidity)
Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.
Score 1 if this year's current ratio is higher, 0 if it's lower
Bicycle Therapeutics's current ratio of this year was 12.66409705. Bicycle Therapeutics's current ratio of last year was 14.85675691.
==> Last year's current ratio is higher ==> Score 0.
Question 7. Change in Shares in Issue
Compare the number of shares in issue this year, to the number in issue last year.
Score 0 if there is larger number of shares in issue this year, 1 otherwise.
Bicycle Therapeutics's number of shares in issue this year was 69.683. Bicycle Therapeutics's number of shares in issue last year was 69.197.
==> There is larger number of shares in issue this year. ==> Score 0.
Efficiency
Question 8. Change in Gross Margin
Compare this year's gross margin (Gross Profit divided by sales) to last year's.
Score 1 if this year's gross margin is higher, 0 if it's lower.
Bicycle Therapeutics's gross margin of this year was 1. Bicycle Therapeutics's gross margin of last year was 1.
==> Last year's gross margin is higher ==> Score 0.
Question 9. Change in asset turnover
Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.
Score 1 if this year's asset turnover ratio is higher, 0 if it's lower
Bicycle Therapeutics's asset turnover of this year was 0.06635258. Bicycle Therapeutics's asset turnover of last year was 0.0474341.
==> This year's asset turnover is higher. ==> Score 1.
Evaluation
Piotroski F-Score
=
Que. 1
+
Que. 2
+
Que. 3
+
Que. 4
+
Que. 5
+
Que. 6
+
Que. 7
+
Que. 8
+
Que. 9
=
0
+
0
+
1
+
0
+
0
+
0
+
0
+
0
+
1
=
2
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Bicycle Therapeutics has an F-score of 2. It is a bad or low score, which usually implies poor business operation.
Bicycle Therapeutics (FRA:50BA) has a Piotroski F-Score of 2 as of Jun. 26, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Bicycle Therapeutics and its competitors. This is 33% below median its historical median of 3.00. Over the past decade, Bicycle Therapeutics' Piotroski F-Score has ranged from 1.00 to 4.00. According to the industry distribution chart, Bicycle Therapeutics ranks #981 out of 1342 companies in the Biotechnology industry, placing it in the top 73.1%.
Is Bicycle Therapeutics' Piotroski F-Score too high?
Bicycle Therapeutics' current Piotroski F-Score of 2 is 33% below median its 10-year median of 3.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 4.00. The Biotechnology industry median Piotroski F-Score is 3.00. Bicycle Therapeutics' value of 2 is 33.3% below this industry median. Based on the distribution chart, Bicycle Therapeutics ranks #981 out of 1342 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Bicycle Therapeutics has a GF Score™ of 57/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Bicycle Therapeutics' Piotroski F-Score compare to ABEO and DMAC?
According to the Biotechnology industry distribution chart, Bicycle Therapeutics ranks #981 out of 1342 companies for Piotroski F-Score. This places Bicycle Therapeutics in the lower half of its industry. The industry median Piotroski F-Score is 3.00. Bicycle Therapeutics' value of 2 is 33.3% below this benchmark. Historically, Bicycle Therapeutics' own Piotroski F-Score has ranged from 1.00 to 4.00 over the past decade. While the company's 10-year median is 3.00 vs. the industry median of 3.00, Bicycle Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Biotechnology company?
The median Piotroski F-Score among Biotechnology companies is 3.00, based on 1,342 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bicycle Therapeutics's current Piotroski F-Score of 2 is 33.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Bicycle Therapeutics and its competitors. For the Biotechnology industry, the median Piotroski F-Score is 3.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bicycle Therapeutics's current Piotroski F-Score is 2, which is 33% below median its own 10-year median of 3.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bicycle Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Bicycle Therapeutics (FRA:50BA) is currently considered Possible Value Trap. The stock's GF Value™ is €12.98, compared to a current price of €3.46 — trading 73.3% below its estimated fair value. The current Piotroski F-Score is 2, which is 33% below median its 10-year median of 3.00 and 33.3% below the Biotechnology industry median of 3.00. Bicycle Therapeutics' overall GF Score™ is 57/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Bicycle Therapeutics (FRA:50BA), the current Piotroski F-Score is 2 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bicycle Therapeutics (FRA:50BA) Overvalued in 2026?
Based on GuruFocus' analysis, Bicycle Therapeutics stock appears to be undervalued.
The current stock price of €3.46 is trading 73.3% below its estimated GF Value™ of €12.98.
GuruFocus considers Bicycle Therapeutics to be Possible Value Trap.
Key valuation signals for FRA:50BA:
Piotroski F-Score: 2 (33% below median its 10-year median of 3.00)
GF Value™: €12.98 vs. price of €3.46 (73.3% below fair value)
Industry Position: 33.3% below the Biotechnology median (#981 of 1342)
No single metric tells the full story. See the FRA:50BA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United Kingdom.
57GF Score
Get the complete analysis for FRA:50BA
Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:50BA has been successfully added to your 
